Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingrui Liu

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Frontiers in Pharmacology|June 14, 2021
A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male SubjectsHong Zhang, Hong Chen, Xiaojiao Li, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitusXiaojiao Li, Xiaoxue Zhu, Jingrui Liu, et al.
Journal of Clinical Laboratory Analysis|June 30, 2020
Evaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemiaChao Yu, Fei Fan, Siqi Hu, et al.
Expert Opinion on Investigational Drugs|January 22, 2026
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drugMengdi Lu, Jing Chen, Hong Zhang, et al.
The Lancet. Infectious Diseases|February 15, 2024
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trialsXiaojiao Li, Yusi Liu, Meng Wang, et al.
JAMA Dermatology|December 11, 2024
Safety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical TrialXiaojiao Li, Bing Li, Deming Yang, et al.
Frontiers in Pharmacology|February 11, 2021
A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese MenHong Zhang, Hong Wang, Haijing Wei, et al.
Frontiers in Pharmacology|December 4, 2023
Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteersXiaojiao Li, Min Wu, Jixuan Sun, et al.
Cellular and Molecular Life Sciences : CMLS|May 22, 2024
Cardiac-specific PFKFB3 overexpression prevents diabetic cardiomyopathy via enhancing OPA1 stabilization mediated by K6-linked ubiquitinationJinlan Luo, Shuiqing Hu, Jingrui Liu, et al.
Clinical Pharmacology in Drug Development|September 26, 2019
Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese SubjectsXiaojiao Li, Jingrui Liu, Changcheng Sheng, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Frontiers in Pharmacology|June 14, 2021
A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male SubjectsHong Zhang, Hong Chen, Xiaojiao Li, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitusXiaojiao Li, Xiaoxue Zhu, Jingrui Liu, et al.
Journal of Clinical Laboratory Analysis|June 30, 2020
Evaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemiaChao Yu, Fei Fan, Siqi Hu, et al.
Expert Opinion on Investigational Drugs|January 22, 2026
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drugMengdi Lu, Jing Chen, Hong Zhang, et al.
The Lancet. Infectious Diseases|February 15, 2024
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trialsXiaojiao Li, Yusi Liu, Meng Wang, et al.
JAMA Dermatology|December 11, 2024
Safety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical TrialXiaojiao Li, Bing Li, Deming Yang, et al.
Frontiers in Pharmacology|February 11, 2021
A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese MenHong Zhang, Hong Wang, Haijing Wei, et al.
Frontiers in Pharmacology|December 4, 2023
Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteersXiaojiao Li, Min Wu, Jixuan Sun, et al.
Cellular and Molecular Life Sciences : CMLS|May 22, 2024
Cardiac-specific PFKFB3 overexpression prevents diabetic cardiomyopathy via enhancing OPA1 stabilization mediated by K6-linked ubiquitinationJinlan Luo, Shuiqing Hu, Jingrui Liu, et al.
Clinical Pharmacology in Drug Development|September 26, 2019
Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese SubjectsXiaojiao Li, Jingrui Liu, Changcheng Sheng, et al.
Pageof 10